February 1, 2006

Lorus’ pancreatic cancer drug shows benefit

TORONTO (Reuters) - Lorus Therapeutics Inc. said on
Wednesday data from Phase 3 trials of its Virulizin(R) cancer
treatment showed a significant survival benefit for a subgroup
of patients.

The Canadian company said the finding from its exploratory
analysis would not be sufficient for regulatory approval
without additional clinical investigation.

Lorus said patients who remained on Virulizin(R)
demonstrated a median survival of 10.9 months, compared with
7.4 months for patients on a placebo.

The late-stage trial compared Virulizin(R) plus gemcitabine
to placebo plus gemcitabine for the treatment of chemonaive
patients with locally advanced or metastatic pancreatic cancer,
as first-line therapy.

An optional Stage 3 second-line therapy included
continuation of Virulizin or placebo alone or in combination
with 5-flurouracil.

The results of the Phase 3 clinical trial were presented at
an international cancer meeting in Paris, France.

($1=$1.14 Canadian)